Courtesy of Benzinga.
Mylan Inc. (Nasdaq: MYL) today commented on a ruling for partial summary judgment in its patent infringement lawsuit against Sunovion Pharmaceuticals Inc. in relation to Sunovion’s Brovana® product. The U.S. District Court for the Southern District of New York granted Sunovion’s motion regarding one of Sunovion’s defenses and its request to limit damages.
Mylan is disappointed in today’s ruling and believes the Court erred in its decision. Mylan intends to appeal the decision. In addition, Mylan’s two reexamined patents remain the subject of ongoing litigation and the company intends to continue to pursue damages and an injunction with respect to those patents.
Mylan also will continue to pursue its claims against Teva in separate litigation.
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.
